MedTrace Logo

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

NCT04670770 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-03-23

No results posted yet for this study

Summary

This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.

Conditions

  • Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG

Drug - SHR1459

Oral Tablets taken once daily for 52 weeks

Sponsors & Collaborators

  • Reistone Biopharma Company Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2022-08-15
Completion
2022-08-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04670770 on ClinicalTrials.gov